In 2010 ataluren has been clinically tested for the treatment of methylmalonic acidemia, an inherited polygenic disease caused by mutations in genes encoding the mitochondrial enzyme methylmalonyl-CoA mutase (MCM) or for adenosylcobalamin (AdoCbl), also known as coenzyme B12. Here, MMUT is linked to methylmalonic acidemia.